Anastasia Chatzidimitriou

Anastasia Chatzidimitriou

Auto-generated profile, based on publicly available information

Anastasia Chatzidimitriou

Institute of Applied Biosciences, Centre for research and technology Hellas, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Seminars in Cancer Biology
Verified
Journal Article
Open access
AAAndreas Agathangelidis
Andreas Agathangelidis
EVElisavet Vlachonikola
Elisavet Vlachonikola
FDFrederic Davi
Frederic Davi
ALAnton W. Langerak
Anton W. Langerak
ACAnastasia Chatzidimitriou
Anastasia Chatzidimitriou
Cancer is characterized by an extremely complex biological background, which hinders personalized therapeutic interventions. Precision medicine promises to overcome this obstacle through integrating information from different 'subsystems', including the host, the external environment, the tumor itself and the tumor micro-environment. Immunogenetics is an essential tool that allows dissecting both lymphoid cancer ontogeny at both a cell-intrinsic and a cell-extrinsic level, i.e. through characterizing micro-environmental interactions, with a view to precision medicine. This is particularly thanks to the introduction of powerful, high-throughput approaches i.e. next generation sequencing, which allow the comprehensive characterization of immune repertoires. Indeed, NGS immunogenetic analysis (Immune-seq) has emerged as key to both understanding cancer pathogenesis and improving the accuracy of clinical decision making in oncology. Immune-seq has applications in lymphoid malignancies, assisting in the diagnosis e.g. through differentiating from reactive conditions, as well as in disease monitoring through accurate assessment of minimal residual disease. Moreover, Immune-seq facilitates the study of T cell receptor clonal dynamics in critical clinical contexts, including transplantation as well as innovative immunotherapy for solid cancers. The clinical utility of Immune-seq represents the focus of the present contribution, where we highlight what can be achieved but also what must be addressed in order to maximally realize the promise of Immune-seq in precision medicine in cancer.

25 June 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
AAAndreas Agathangelidis
Andreas Agathangelidis
CGChrysi Galigalidou
Chrysi Galigalidou
LSLydia Scarfò
Lydia Scarfò
TMTheodoros Moysiadis
Theodoros Moysiadis
ARAlessandra Rovida
Alessandra Rovida
PGPaolo Prospero Ghia
Paolo Prospero Ghia

2 November 2023 in Blood
Verified
Journal Article
Open access
MGMarina Gerousi
Marina Gerousi
GGGeorgios Gavriilidis
Georgios Gavriilidis
SKSofoklis Keisaris
Sofoklis Keisaris
AKArtemis Kourouni
Artemis Kourouni
AOAspasia Orfanou
Aspasia Orfanou
KXKonstantinos Xanthopoulos
Konstantinos Xanthopoulos
Disclosures. Chatzidimitriou:Novartis: Other; Jansenn: Other. Ghia:Roche: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria, Research Fundin

6 October 2026 in HemaSphere
Verified
Journal Article
Open access
GTGrigorios Tsaknakis
Grigorios Tsaknakis
IMIrene Mavroudi
Irene Mavroudi
MRMarco Roncador
Marco Roncador
APAnna Maria Perantonaki
Anna Maria Perantonaki
EBErasmia Boutakoglou
Erasmia Boutakoglou
Helen PapadakiHelen Papadaki
Helen Papadaki
Characterization of the presence and evolution of clonal hematopoiesis (CH) in patients with unexplained cytopenias is fundamental to risk‐stratifying patients and optimizing clinical surveillance for malignant progression. We investigated the mutational spectrum and clonal metrics in a cohort of 256 patients with chronic idiopathic neutropenia (CIN)—clinically overlapping with idiopathic cytopenia of undetermined significance with isolated neutropenia (ICUS‐N)—and assessed clonal presence and dynamics through longitudinal tracking of 104 patients with a median follow‐up of 32 months. CH was identified in 12.5% of patients, primarily involving single DNMT3A or TET2 mutations. Longitudinal analysis revealed two distinct mutational patterns: an age‐related pattern, predominantly involving DNMT3A and TET2 single mutations, which showed marginal changes in clone size and associated with stable disease course, and a high‐risk pattern, primarily driven by SRSF2 and IDH1/2 mutations, characterized by higher clonal expansion and a high risk of malignant progression. Malignant transformation in CIN was significantly associated with baseline variant allele frequency (VAF) (VAF > 10%), the presence of multiple mutations, and detection of specific driver mutations ( SRSF2 , IDH1/2 ). An annual VAF increase (ΔVAF/year) ≥7.5% was found to optimally predict evolution, thus showing that clonal dynamics can serve as an indicator of disease outcome. Longitudinal assessment of peripheral blood hematologic parameters was found not to display clinically significant changes. These findings provide important insight into high‐risk evolutionary patterns in CIN and underscore the importance of longitudinal monitoring with next‐generation sequencing (NGS) for clinical decision‐making and risk‐adapted management in CIN patients with clonal cytopenia.